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Introduction. Small bowel cancers are rare. Accumulation of data regarding their clinical presentation, pathologic features,
prognostic factors, treatment modalities, and outcome is diﬃcult. Methods. This is a retrospective study of the medical records
of 33 patients with small bowel cancers treated at the American University of Beirut-Medical Center over a 20-year period. Results.
The study included 25 males (76%) and 8 females (24%). Median age at presentation was 56 years. Most common symptoms were
abdominal pain (66.7%) and weight loss (57.6%). Thirteen patients presented with abdominal emergencies (39.3%). Lymphoma
wasthemostcommonmalignanttumor(36.4%),followedbyadenocarcinoma(33.3%),leiomyosarcoma(15.2%),gastrointestinal
stromal tumors (12.1%), and neuroendocrine tumors (3.0%). Tumors were located in the duodenum in 30% of patients, jejunum
in 33%, and ileum in 36%. Resectability rate was 72.7% and curative R0 resection was achieved in 54.1% (13/24) of patients.
5-year survival of the 33 patients was 24.2%. Conclusion. Small bowel cancers are diﬃcult to diagnose because of the nonspeciﬁc
symptoms. Most patients present with advanced disease and have poor prognosis. Adenocarcinoma and duodenal location have
the worst 5-year survival in contrast to stromal tumors and those with ileal location which have the best survival.
Copyright © 2008 Mirna H. Farhat et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Small bowel cancers are uncommon tumors of the gastroin-
testinal tract. As a result of their infrequency and variety, the
accumulation of data regarding their clinical presentation,
pathologicfeatures,prognosticfactors,treatmentmodalities,
and outcome has been diﬃcult.
This study was conducted to review the experience with
small bowel tumors of 33 patients seen at the American
University of Beirut Medical Center.
2. Patientsand Methods
During a 20-year period (1986–2006), 33 patients were
treated for small bowel tumors at the American University
of Beirut Medical Center. Approval was obtained from
the Institutional Research Board. Data obtained from the
medical records were gathered regarding standard demo-
graphic data, presenting signs and symptoms, comorbid
medical illnesses, diagnostic workup, operative procedures,
pathologicdiagnosis,andsubsequentfollow-upvisitstodoc-
ument the recurrence of previous or subsequent associated
primary cancers. Recurrence was deﬁned as biopsy-proven
tumor or radiologic evidence of obvious local or distant
recurrence.
Periampullary tumors, secondary, and benign tumors of
the small bowel were excluded. Staging of patients was done
according to the TNM classiﬁcation system and AJCC for
small bowel tumors [1], except for lymphomas.
Survival duration was measured from the time of
diagnosis to the last follow-up evaluation or death. Follow-
up data was obtained from patient medical records or from
telephone interviews with the patient or family members.
Follow-up data was available on 30 out of 33 patients.2 Journal of Oncology
Table 1: Patient characteristics and clinical presentation.
No. of patients (%)
Age
<50 11 (33.3)
≥50 22 (66.7)
Gender
Male 25 (75.8)
Female 8 (24.2)
Symptom
Abdominal pain 22 (66.7)
Weight loss 19 (57.6)
Nausea/vomiting 9 (27.0)
Bowel obstruction 8 (24.0)
GI bleeding 8 (24.0)
Anemia 7 (21.0)
Bowel perforation 4 (12.0)
Acute abdomen 4 (12.0)
Jaundice 4 (12.0)
Constipation 3 (9.0)
All data was coded and entered using “SPSS 15.0”
computer program.
3. Results
3.1. Demographic Data. This study included 33 patients with
histologically conﬁrmed small bowel malignancies. They
were 25 males (76%) and 8 females (24%) patients. The male
to female ratio was 3.1:1 with a median age at presentation of
56years(range:23–77).Two-thirdsofthepatientswereolder
than 50 years (Table 1).
There was a history of Crohn’s disease in one patient,
ulcerative colitis in another one, and celiac disease in a third
one. One-third of the patients were smokers (11/33). Three
patients(9.1%)hadahistoryofanotherprimarymalignancy
(mucinous cystadenocarcinoma of ovary, biopsy-proven
cholangiocarcinoma, and leiomyosarcoma of the thigh).
Most complaints were nonspeciﬁc and these included
in decreasing order abdominal pain (66.7%), weight loss
(57.6%), followed by nausea and vomiting (27%) (see
Table 1). Thirteen patients presented with emergencies such
as bowel obstruction (n = 8, 24%) and bowel perforation
(n = 4, 12%). Of the four patients that had perforation,
three had lymphomas and one had leiomyosarcoma. Acute
abdomen was the initial presentation in four patients (12%).
Endoscopy was performed on 10 out of 33 patients. It
detected the tumor in 7 only (6 duodenum, 1 ileum) and
it failed to detect the disease in 3 patients, all of which had
ileal disease. Upper GI series was performed on 12 out of 33
patients. The disease was detected in 11 patients (4 jejunum,
6 duodenum, 1 ileum) and missed in one patient having a
tumor in the ileum.
Computed tomography was used in 13/33 patients and
emergent laparatomy in 4/33.
Table 2: Distribution of small bowel tumors by pathology and
anatomical distribution.
Duodenum Jejunum Ileum No. (%)
Lymphoma 2 4 6 12 (36.4)
Adenocarcinoma 7 1 3 11 (33)
Leiomyosarcoma 0 3 2 5 (15.2)
GIST
∗ 1 3 0 4 (12.1)
Neuroendocrine 0 0 1 1 (3.0)
Total (%) 10 11 12 33
Table 3: Treatment modalities oﬀered to 33 patients with small
bowel tumors.
Modality No. (%)
No treatment 4 12.1
Complete resection 12 36.3
Complete resection + chemotherapy 6 18.1
Incomplete resection 4 12.1
Incomplete resection + chemotherapy 2 6.0
Chemotherapy (palliative) 5 15.1
Table 4: Types of surgeries performed for small intestine tumors.
Surgery No. of patients (26) (%)
Whipple 5 (16.6)
Duodenal resection 2 (6.6)
Jejunal resection 9 (30)
Ileal resection 5 (16.6)
Right hemicolectomy 3 (10)
Bypass 2 (6.6)
3.2. Characteristics of the Tumors. Four diﬀerent histologic
types of tumors were identiﬁed. Lymphoma was the most
common tumor (36.4%), followed by adenocarcinoma
(33.3%), leiomyosarcoma (15.2%), gastrointestinal stromal
tumors (GISTs) (12.1%), or neuroendocrine tumors (3.0%)
(see Table 2).
Table 2 shows the anatomical distribution of the tumors
with respect to histology. The tumor was located in the
duodenum in 30% of patients, jejunum in 33%, and ileum in
36%. Most adenocarcinomas were located in the duodenum
(7/10), in contrast to most lymphomas (10/12) and all
leiomyosarcomas (5/5) that were located in the jejunum and
ileum.
3.3. Treatment. Surgical resection was carried out in 24 out
of 33 patients. Resectability rate was 72.7% and R0 resection
was achieved in 54.1% (13/24) of patients (see Table 3). Two
patients underwent palliative double bypass surgery. Four
patients were deemed unresectable because of peritoneal
metastasis, locally advanced disease, and vascular invasion.
T h es u r g i c a lp r o c e d u r e sp e r f o r m e da r el i s t e di nTable 4.
There were four cases of tumor recurrence.
Reoperation was performed in 5 patients for the follow-
ing reasons: tumor recurrence, metastasis, and postoperative
complications. Emergent laparatomy was performed in 4Journal of Oncology 3
Table 5: TNM staging of small bowel malignancies, excluding
lymphoma. (Adapted from the AJCC Cancer Staging Manual, 6th
Edition (2002), Springer New York) .
Stage Primary tumor1 Regional lymph
nodes
2 Distant metastasis
3
I T1/T2 N0 M0
II T3/T4 N0 M0
III Any T N1 M0
IV Any T Any N M1
1Primary tumor
T1: tumor invades lamina propria or submucosa;
T2: tumor invades muscularis propria;
T3: tumor invades through muscularis propria into the subserosa;
T4: tumor perforates the vascular peritoneum or directly invades other
organs, including mesentery, abdominal wall, and pancreas.
2Regional lymph nodes
N0: no regional lymph nodes metastasis;
N1: regional lymph nodes metastasis.
3Distant metastasis
M0: no distant metastasis;
M1: distant metastasis.
Table 6: Stage and grade of small bowel tumors.
Grade N (%)
Well 3 (9)
Moderate 5 (15)
Poor 4 (12)
N/A 21 (64)
Stage
I2 ( 6 )
II 9 (27)
III 8 (24)
IV 7 (21)
N/A 7 (21)
patients (3 lymphoma and 1 leiomyosarcoma). Chemother-
apy was administered to 13 patients (39.3%).
3.4. Tumor Characteristics. Tumor size was available on 27
patients. Sixteen patients (59%) had tumors greater than
5cm, 8 patients (30%) had tumors less than 3cm, and 3
patients (11%) had tumor sizes between 3 and 5cm.
Tumor grade was available for 12 patients (36.4%).
Among the 12 patients, 8 patients (66.7%) had well or mod-
erately diﬀerentiated tumors and 4 had poorly diﬀerentiated
tumors (33.3%) (see Table 5).
TNM staging was available on 26 patients (78.7%).
According to AJCC staging of small bowel malignancies
(Table 5), tumors in our study were classiﬁed as stage I (n =
2), stage II (n = 9), stage III (n = 8), stage IV (n = 7)
(see Table 6). Almost half of the patients presented with
metastatic disease (stage III/IV). Lymph nodes (10/33) were
the most common site involved by metastasis followed by
the liver (5/33), lung (3/33), brain (1/33), bone (1/33), and
omentum (1/33).
Table 7: Survival of small intestine tumors at 1, 3, and 5 years by
location.
1 year (%) 3 years (%) 5 years (%)
Duodenum 50% 40% 10%
Jejunum 50% 20% 20%
Ileum 62.5% 37.5% 37.5%
Table 8: Survival of small intestine tumors at 1, 3, and 5 years by
histology.
1 year (%) 3 years (%) 5 years (%)
Adenocarcinoma 30% 20% 10%
Lymphoma 36.4% 27.3% 18.2%
Leiomyosarcoma 60% 20% 20%
GIST 100% 75% 50%
3.5. Survival. Survival analysis of the 33 patients showed
that 51.5%, 33.3%, and 24.2% were alive at 1, 3, and 5
years, respectively. Three patients were lost to follow-up.
Mean survival rates for the diﬀerent malignancies were 22.03
months for adenocarcinomas, 52.85 months for lymphomas,
47.6 months for leiomyosarcoma, and 64.9 months for GIST.
1-, 3-, and 5-year survivals for the diﬀerent tumor loca-
tions and histologies are listed in Tables 7 and 8,r e s p e c t i v e l y .
However, the number of patients in some categories was
small which could have aﬀected the signiﬁcance of some of
these rates.
4. Discussion
Neoplasms of the small intestine are unusual and constitute
less than 3% of all gastrointestinal tract cancers [2–4]. These
tumors are known for their rarity, variability, nonspeciﬁc
symptomatology, diagnostic diﬃculties, delayed presenta-
tion, and overall poor prognosis [2].
Over 90% of cases occur in people over the age of 40 [5]
with a median age at diagnosis of 55 years [6, 7]a n dm e n
tend to be more aﬀected by the tumors than women [5, 8],
which is in agreement with our results.
Abdominal pain, weight loss, nausea, and vomiting were
the most common presenting symptoms for small bowel
tumors in this study, which is similar to ﬁndings reported
in previous studies [7, 9]. Bleeding is more common with
carcinomas; perforation is more common with lymphomas,
while obstruction is common to all enteric malignancies
[10]. No distinct presentation by pathology was evident in
our study.
The lack of symptom speciﬁcity in patients suﬀering
from small intestinal malignancies and failure to evaluate
the small bowel, which is a blind spot to routine endoscopic
and radiological diagnostic tests, have been considered as a
contributing factor to the late presentations of the disease
and eventually the delay in diagnosis [11].
Histologically, small bowel tumors are of diﬀerent
subtypes, with adenocarcinoma being the most frequent
(47%) followed by carcinoid tumors (28%), GI lymphomas4 Journal of Oncology
(12%), and GI sarcomas (12%) [2, 3, 7, 12]. In this study,
lymphomas were the most common type, followed by
adenocarcinomas, sarcomas, and stromal tumors.
On average, adenocarcinomas are distributed more
proximally in the small intestine, most frequently in the
duodenum followed by the jejunum and ileum, whereas
lymphomas are more common distally, with nearly equal
distribution between the jejunum and the ileum [5, 7, 8,
13]. Carcinoid tumors are distributed throughout the small
intestines, but are located preponderantly in the ileum.
Sarcomas are found most often in the jejunum [7]. In
our study, adenocarcinomas were mostly located in the
duodenum, while sarcomas and lymphomas were mostly
located in the more distal parts of the small bowel.
Small bowel tumors were noticed to be associated with
an increased incidence of second malignancies [2, 4, 13].
Treadwell and White reported second tumor occurrence
in 43% of patients with primary small bowel tumors [4],
whereas Ripley and Weinerman noted an 8-fold increase
in second malignancies with small bowel carcinoma with
73% of the tumors occurring before the diagnosis of the
small bowel malignancy [13]. The incidence of a second
malignancy approached 9% in our series.
Surgical resection remains the cornerstone of therapy
for these malignancies [11]. Cunningham et al. showed a
signiﬁcantly longer median survival for the resected group
(26monthsversus11months)[14].Muchoftheinformation
on the eﬀectiveness of surgery for early GI lymphoma
is based on limited, retrospective reviews that do not
speciﬁcally compare primary surgical therapy with primary
medicalmanagementareeitherchemotherapy,radiotherapy,
or radiochemotherapy.
Regardless of surgical resection, the overall 5-year sur-
vival rate for small bowel cancers ranges between 20 and
50% [2, 6, 7, 14, 15]. Their disappointing course seems to be
related to the delay in diagnosis because of the nonspeciﬁc
symptoms [8]. In our study, the 5-year survival rates of
GIST (50%) were higher than those of adenocarcinomas and
lymphomasandareclosetothe67%5-yearsurvivalreported
by Egberts et al. [16]. Therefore, early surgical intervention
withahighindexofsuspicionisrequiredtoimprovesurvival
[17].
Giventhelowprevalenceofthisdisease,fewclinicaltrials
of chemotherapy have been conducted and despite a variety
of chemotherapeutic agents used to treat adenocarcinoma of
the small bowel, no standard chemotherapy regimen exists
for this disease. Many oncologists extrapolate information
from trials of large bowel carcinomas or upper gastrointesti-
nal tumors, and apply similar chemotherapy regimens in
the treatment of advanced small bowel adenocarcinoma. In
one of the largest retrospective reviews conducted, the M. D.
Anderson Cancer Center (Tex, USA) reviewed 217 patients
with small bowel adenocarcinoma and showed that the use
of adjuvant chemotherapy administered to 59 patients had
no survival beneﬁt [6].
The most important limitation in our study is the small
number of patients. This has limited our ability to determine
the signiﬁcance of the diﬀerence in survival among the
various groups.
In summary, small bowel tumors are uncommon. They
are diﬃcult to diagnose because of the nonspeciﬁc symp-
toms. They also have a poor prognosis because most patients
present with advanced disease. In our report, adenocar-
cinoma and duodenal location showed the worst 5-year
survival, while stromal tumors and ileal location had the best
5-year survival.
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